Adam Cutler
Hope your proud of yourselves in releasing results that requires a treasure map to decipher. You really need to dumb it down or change the language so that your shareholders can interpret the findings.. Some of the analyst appear to also lack the depth and knowledge of HBV to properly evaluate the results. Folks looking at comparable data shouldn't need to know the difference between HBeAG Negative and Positive to understand that results may differ, that's your job to tell us the road taken by ABUS is much harder.